Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results
I'm PortAI, I can summarize articles.
William Blair analyst Andy Hsieh maintained a Hold rating on Nektar Therapeutics (NKTR) due to mixed results from the rezpegaldesleukin (rezpeg) trial for alopecia areata. The drug showed some clinical activity but did not achieve statistical significance on its primary endpoint. Excluding protocol violations, efficacy improved, but it was still less effective than Olumiant. This led to a cautious stance and a Hold rating. Another report also reiterated a Hold rating with a $58.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments